Actinium Pharmaceuticals, Inc.(ATNM)

$1.02—

Chart

Actinium Pharmaceuticals, Inc.(ATNM)

NYSE

$1.02—

Chart Studio

ATNM(ATNM)

ATNM

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.27

Nov 13, 2026

Revenue Estimate

$1M

FY2026E EPS$0.14

Analyst Sentiment

Wall St. Consensus

Buy

11 analysts·Moderate coverage

Score

11 Buy (100%)0 Hold (0%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

11100%

Hold

00%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$4.00

+292.2%

Consensus

$4.95

+385.3%

Bull

$24.26

+2278.4%

12-Month Target Range11 analysts

$4.00$4.95$24.26

Current $1.02Consensus

Current Price

$1.02

Upside to Consensus

$3.93

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev-44.60%

EPS—

FY2028

Rev-80.40%

EPS—

FY2029

Rev+3881.63%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$35M	$19M	$4M	$151M	$7M
Low	$35M	$19M	$4M	$151M	$7M
High	$35M	$19M	$4M	$151M	$7M
EBITDA Avg	$10M	$-11M	$-23M	$10M	$10M
Low	$10M	$-11M	$-35M	$10M	$10M
High	$10M	$-11M	$12M	$10M	$10M
EBIT Avg	$6M	$-16M	$-27M	$-8M	$-6M
Low	$6M	$-16M	$-39M	$-8M	$-6M
High	$6M	$-16M	$7M	$-8M	$-6M
Net Income Avg	$4M	$-16M	$-27M	$-8M	$-6M
Low	$4M	$-16M	$-39M	$-8M	$-6M
High	$4M	$-16M	$6M	$-8M	$-6M
EPS Avg	$0.14	$-0.53	$-0.52	$-0.26	$-0.18
Low	$0.14	$-0.53	$-1.26	$-0.26	$-0.18
High	$0.14	$-0.53	$0.18	$-0.26	$-0.18
Analysts (Rev / EPS)	2 / 1	2 / 2	3 / 3	1 / 1	2 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$1M	$2M	$21M	$17M	$15M	$12M
Low	$1M	$2M	$21M	$17M	$15M	$12M
High	$1M	$2M	$21M	$17M	$15M	$12M
EBITDA Avg	$-8M	$-7M	$-2M	$-1M	$-1M	$-808,088
Low	$-8M	$-7M	$-2M	$-1M	$-1M	$-808,088
High	$-8M	$-7M	$-2M	$-1M	$-1M	$-808,088
EBIT Avg	$-8M	$-7M	$-3M	$-3M	$-3M	$-3M
Low	$-8M	$-7M	$-3M	$-3M	$-3M	$-3M
High	$-8M	$-7M	$-3M	$-3M	$-3M	$-3M
Net Income Avg	$-8M	$-7M	$-3M	$-3M	$-3M	$-3M
Low	$-8M	$-7M	$-3M	$-3M	$-3M	$-3M
High	$-8M	$-7M	$-3M	$-3M	$-3M	$-3M
EPS Avg	$-0.26	$-0.23	$-0.09	$-0.08	$-0.08	$-0.08
Low	$-0.26	$-0.23	$-0.09	$-0.08	$-0.08	$-0.08
High	$-0.26	$-0.23	$-0.09	$-0.08	$-0.08	$-0.08
Analysts (Rev / EPS)	4 / 1	4 / 1	4 / 1	4 / 1	4 / 1	4 / 1

Earnings Surprises

Recent Analyst Actions

Aug 6, 2024Maxim Group

Actinium Pharmaceuticals price target lowered to $5 from $30 at Maxim

Target:$5.00

+103.3%from $2.46

Aug 6, 2024H.C. Wainwright

Actinium Pharma (ATNM) PT Lowered to $4 at H.C. Wainwright

Target:$4.00

+50.4%from $2.66

May 13, 2024Stephens

Actinium Pharmaceuticals initiated with an Overweight at Stephens

Target:$25.00

+191.0%from $8.59

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance